Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trialBenjamin A. Fisher, K Turner, Duncan Richards et al.|UCL Discovery (University College London)|2022Cited by 58
Supplementary Materials and Methods from Neuroblastoma Arginase Activity Creates an Immunosuppressive Microenvironment That Impairs Autologous and Engineered ImmunityFrancis Mussai, Carmela De Santo, Sharon A. Egan et al.|Unknown|2023Cited by 0
Supplemental figures 1-5 from Neuroblastoma Arginase Activity Creates an Immunosuppressive Microenvironment That Impairs Autologous and Engineered ImmunityFrancis Mussai, Carmela De Santo, Sharon A. Egan et al.|Unknown|2023Cited by 0
Supplementary Figure Legends from Neuroblastoma Arginase Activity Creates an Immunosuppressive Microenvironment That Impairs Autologous and Engineered ImmunityFrancis Mussai, Carmela De Santo, Sharon A. Egan et al.|Unknown|2023Cited by 0
Supp tables 1 and 2 from Neuroblastoma Arginase Activity Creates an Immunosuppressive Microenvironment That Impairs Autologous and Engineered ImmunityFrancis Mussai, Carmela De Santo, Sharon A. Egan et al.|Unknown|2023Cited by 0